amiridine and Craniocerebral-Trauma

Effects of neyromidin and cerebrolysin on clinical and electrophysiological patterns of neurodynamic disorders during traumatic brain injury were studied. The study involved 50 patients, aged from 21 to 58 years, with mild craniocerebral injury in subacute period. Patients were stratified into two groups. Patients of the first group (n=25) were treated with the general drugs (vasoactive and nootropic preparations, vitamins) as well as with neyromidin in dosage of 15 mg intramuscularly 1 time a day during 10 days. The second group of patients (n=25) received both general treatment and 10 ml of cerebrolysin intravenously 1 time a day during 10 days. The whole investigation lasted for 20 days. Besides the standard neurological examination, the Hamilton anxiety rating scale (HARS), Multidimensional Fatigue Symptom Inventory-short form (MFSI-SH, general fatigue was assessed) and Kerdo index were administered. We have also evaluated somatosensory evoked potentials and performed magnetic diagnostics to calculate central motor conduction time. The analysis of the results suggests that the two investigated drugs have a beneficial effect on the neurodynamic disorders in case of the craniocerebral injury. Nevertheless, the impact of neyromidin was more apparent and valid throughout the whole study.

Topics: Adult; Amino Acids; Aminoquinolines; Cerebral Cortex; Craniocerebral Trauma; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Treatment Outcome; Young Adult

To assess efficacy and tolerability of axamon (ipidacrine) in the complex therapy of patients with cranial-brain injuries, 40 patients have been studied. Patients of the main group (20 persons) received, along with traditional therapy, axamon in dose 0,02 g 3 times daily during 2 months and patients of the control group (20 persons) received only traditional therapy. Clinical examination and assessment with NIS, Autonomic Symptoms Questionnaire, Hamilton anxiety scale, electrophysiological study (magnetic diagnostics, electroneuromyography with investigation of somatosensory evoked potentials, brain CT (MRI) have been conducted at the beginning of treatment and 1 and 2 months after. Axamon demonstrated the highest efficacy (p<0.05) in stopping anxiety symptoms in patients of the main group in the 1st month of treatment. After 2 months, a significant improvement of patient's state in the main group assessed by NIS and Hamilton anxiety scale (p<0.05) was found. Data of electrophysiological and neuroimaging study revealed significant positive changes reflected in the normalization of intracerebral conductance and resolution of structural changes of brain substances in the injury. Side-effects of the drug were brief and did not lead to stopping treatment.

Topics: Aged; Aminoquinolines; Anxiety; Cholinesterase Inhibitors; Craniocerebral Trauma; Dose-Response Relationship, Drug; Electroencephalography; Electromyography; Evoked Potentials, Somatosensory; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Surveys and Questionnaires; Tomography, X-Ray Computed; Trauma Severity Indices; Treatment Outcome